Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.616985
+0.0615 (11.07%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Barinthus Biotherapeutics Stock Forecast
BRNS's stock price has decreased by -58.81% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, Barinthus Biotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.50. The average 1-year stock price forecast is 791.43% higher than the current stock price, while the lowest is $4.00 (+548.31%) and the highest is $7.00 (+1,034.55%).
Price Target: $5.50 (+791.43%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Barinthus Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Oct '25 | Nov '25 | Dec '25 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Alliance Global Partners | Alliance Global Partners | Buy Reiterates $7 | Buy | Reiterates | $7 | +1,034.55% | Mar 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.15
from -1.52
EPS Next Year
-1.15
from -1.15
EPS and Forward PE are based on non-GAAP adjusted numbers.